The Importance of Recognizing Interstitial Lung Disease in the Clinical Setting, and the Impact of EGFR Tyrosine Kinase Inhibitors During the Pandemic
To ensure optimal treatment selection and outcomes, differentiating between COVID-19 infection and interstitial lung disease is critical.
Efficacy of osimertinib as adjuvant therapy was demonstrated in ADAURA, a randomized, double-blind, placebo-controlled trial.
Positive findings from this study support channeling additional resources into telemedicine care for lung cancer, and into future randomized controlled trials to verify effectiveness.
The COVID-19 pandemic has highlighted how critical it is to maintain resilience and flexibility of the healthcare system and healthcare providers.
Clinical data are highlighted, providing an understanding of the benefits of treatment with tyrosine kinase inhibitors.
PARP Inhibitors Have Acceptable Toxicity Profiles and Have Shown Efficacy in Treatment of Ovarian Cancer
Emerging evidence suggests PARP inhibitors have the potential to revolutionize the treatment of ovarian cancer.
Olaparib plus Bevacizumab Has Been Approved as Maintenance Therapy for Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
Patients with advanced ovarian cancer may be eligible to receive frontline maintenance treatment with olaparib plus bevacizumab.
Ovarian cancer survivors frequently use adaptive and problem-focused coping strategies. During the COVID-19 pandemic, virtual technology has played a key role in shaping and determining these strategies.
Oral treatments for ovarian cancer can be taken at home, in a sequestered environment that may minimize undue risks for patients. Results from a randomized phase 3 study suggest oral PARP inhibitor therapy has improved efficacy when compared with intravenous chemotherapy.
Telemedicine may play a critical role by creating pathways for overcoming obstacles to healthcare access, particularly for breast cancer reconstruction.
Preliminary recommendations made based on cases from the SOLAR-1 trial suggest that alpelisib-induced hyperglycemia can be managed with early detection, close monitoring, and prompt intervention.
Cost Analysis of Neratinib in an Extended Adjuvant Treatment Setting for Patients with Early-Stage, HR-Positive, HER2-Positive Breast Cancer
For patients with early HR-positive, HER2-positive breast cancer who initiated neratinib within 1 year of completing trastuzumab and in patients who did not achieve a pathologic complete response after neoadjuvant treatment, neratinib may be a cost-effective treatment option.
Effect of Multiple Certified Educational Activities on Knowledge and Competence with CDK4/6 Inhibitors in HR-Positive Breast Cancer
Participation in certified educational activities resulted in significant improvements in knowledge, competence, and confidence regarding the use of CDK4/6 inhibitor therapies in the management of patients with advanced HR-positive breast cancer.
Randomized Phase 3 Trial of Endocrine Therapy plus Entinostat in Patients with HR-Positive Advanced Breast Cancer
The combination of exemestane and entinostat did not show survival benefit in patients with aromatase inhibitor–resistant, HR-positive, HER2-negative advanced breast cancer.
Analysis of Ribociclib plus Letrozole in Male Patients with HR-Positive, HER2-Negative Advanced Breast Cancer
Subgroup analysis of the phase 3b CompLEEment-1 clinical trial supports the use of ribociclib combined with letrozole in HR-positive, HER2-negative advanced breast cancer male patients based on demonstrated efficacy and safety.
In a predominantly black, low-income population, women with diabetes and incident localized breast cancer had decreased overall survival when compared with those without diabetes.
Subgroup analysis of the phase 3b CompLEEment-1 clinical trial reinforces the efficacy and safety of ribociclib plus letrozole in premenopausal patients with HR-positive, HER2-negative advanced breast cancer.
Evaluation of an Alternative Schedule of Palbociclib in Patients with HR-Positive, HER2-Negative Metastatic Breast Cancer
An alternative schedule of palbociclib reduced grade ≥3 neutropenia and showed efficacy data comparable with previous reports.
Study of Adherence to and Patient Satisfaction with Exemestane and Everolimus in Postmenopausal Women with HR-Positive, HER2-Negative Advanced Breast Cancer
Findings from this study show that based on the adjusted adherence rate of the combination therapy of exemestane and everolimus, a low-rate adherence was observed.
Consistent with previous phase 3 studies with ribociclib and letrozole, few patients with HR-positive, HER2-negative advanced breast cancer and central nervous system metastases discontinued treatment due to side effects.
Page 1 of 4
Results 1 - 30 of 110
Results 1 - 30 of 110